Hormonal
Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.
If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.
Evidence demonstrates that GLP-1 RA therapy significantly reduces the incidence of MACE (non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in this population, with relative risk reductions approaching 20%. Crucially, independent of the magnitude of weight loss, consistent improvements are observed in endothelial function...
Why this rating
Based on large-scale randomized clinical trials (SELECT trial) and meta-analyses.
Source
Impact of GLP-1 receptor agonists on cardiovascular risk reduction in patients with obesity without type 2 diabetes mellitus: a systematic review
Paquita del Rocío Quizhpe Donoso et al. · International Journal of Research in Medical Sciences · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →